Genetic Technologies Limited (NASDAQ:GENE)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.39 and traded as high as $1.82. Genetic Technologies shares last traded at $1.78, with a volume of 6,863 shares trading hands.
Separately, ValuEngine raised Genetic Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th.
The firm has a fifty day moving average of $1.98 and a two-hundred day moving average of $1.39.
Genetic Technologies Company Profile (NASDAQ:GENE)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.